Effects of diflunisal on platelet function and fecal blood loss

David Green*, Richard O. Davies, Geoffrey I. Holmes, Helga Kohl, Robyn B. Lee, Nancy Reynolds, Frank R. Schmid, Chunghsin Ts'ao

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The effects of diflunisal, a nonacetylated difluorinated salicylate, on platelet function were compared with those of aspirin and placebo. In a randomized, double-blind trial, normal subjects were given diflunisal, 250, 500, or 1,000 mg twice daily; aspirin, 650 or 1,300 mg twice daily; or placebo for 8-day periods. Diflunisal, 250 mg, had no effect on platelet function, whereas 500 mg induced minimal inhibition of collagen-induced release of platelet serotonin, and 1,000 mg inhibited platelet malondialdehyde production, moderately prolonged template bleeding times (P = NS), and increased fecal blood loss (P < 0.05). In contrast, aspirin, 650 mg, markedly inhibited collagen-induced platelet aggregation and serotonin release, and 1,300 mg prolonged bleeding time (P < 0.01) and increased fecal blood loss (P < 0.01). The effects of aspirin lasted for up to 5 days, whereas changes induced by diflunisal had returned to baseline 24 hr after the drug was discontinued. We conclude that in doses in the same range as those of aspirin diflunisal inhibits platelet function less.

Original languageEnglish (US)
Pages (from-to)378-384
Number of pages7
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - Sep 1981

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effects of diflunisal on platelet function and fecal blood loss'. Together they form a unique fingerprint.

Cite this